drugset / Trial / NCT02805660
Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Non-randomizedSequentialOpen-labelTreatment
Summary
Mocetinostat (MGCD0103) is an orally administered HDAC inhibitor. Durvalumab (MEDI4736) is a human monoclonal antibody that is an inhibitor of the Programmed Cell Death Ligand (or PD-L1). Durvalumab is also known as a checkpoint inhibitor. This study is evaluating the combination regimen of mocetinostat and durvalumab in participants with Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer.
Timeline
- Start
- 2016-06-01
- Primary completion
- 2019-12-14
- Completion
- 2019-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Mocetinostat | Small molecule | 50 mg | Oral |
| Subject | Mocetinostat | Small molecule | 70 mg | Oral |
| Subject | Mocetinostat | Small molecule | 90 mg | Oral |